Home › Filings & Releases › November 2026

Filings & Releases — November 2026

533 documents from 202 companies (279 releases) · updated Nov 7, 2026

Company

All filings (+52)

Friday, November 647

ZBIOZenas BioPharma8-KCurrent report: other eventsWith SunStone weeks away, Zenas quietly reloaded its ATM program after-hours on Friday — resetting to a fresh $200M capacity after drawing ~$153M from the prior tranche, a move that lands before the binary and not reflected in today's +9% session close.
ZBIOZenas BioPharma424B5Prospectus supplement (offering)Summary on the 8-K
XNCRXencorSCHEDULE 13G/A13G amendment
XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
XENEXenon PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
VRDNViridian TherapeuticsReleaseViridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
VIRVir BiotechnologySCHEDULE 13D/A13D amendment
TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
TARAProtara TherapeuticsReleaseProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update → BD updateSummary on the 8-K
TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED NOVEMBER 6, 2026, ISSUED BY THE REGISTRANT → BD updateProtara just bought its own manufacturing facility for $8.75M, completed THRIVE-3 Phase 2b enrollment with interim data due by year-end, and confirmed ADVANCED-2 BCG-Unresponsive enrollment wraps Q4 — a dense catalyst stack into a name trading at ~41% below the post-ASCO close.
TARAProtara Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
RNACCartesian TherapeuticsSCHEDULE 13G/A13G amendment
REPLReplimune Group10-Q/AQuarterly report (amended)
RAREUltragenyx PharmaceuticalReleaseUltragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Pvia aggregator
QTTBQ32 BioSCHEDULE 13G/A13G amendment
QTTBQ32 BioSCHEDULE 13G/A13G amendment
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
QNRXQuoin Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
PTGXProtagonist Therapeutics10-QQuarterly report → BD updateThe Q3 10-Q confirms the buyback is real ($5.8M executed, $294.2M remaining), drops ICONIC-ASCEND data for the first time (70% IGA 0/1 vs placebo, non-inferior to ustekinumab), and adds an NCCN Category 1 guideline win for MIMRYLO — while the ICOTYDE royalty line goes dark for a third straight quarter.
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
PCVXVaxcyteSCHEDULE 13G/A13G amendment
PCVXVaxcyteSCHEDULE 13G/A13G amendment
OCGNOcugenDEFA14AProxy soliciting material
OCGNOcugenDEFA14AProxy soliciting material
NKTXNkartaReleaseNkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
NKTXNkarta8-KCurrent report: Reg FD disclosure · EX-99.1
KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
INKTMiNK TherapeuticsReleaseMiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
IMRXImmuneeringReleaseAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026The Q4 2026 preclinical SITC catalyst just landed with more force than expected: atebimetinib + anti-PD-1 cured 50% of mice in a RAS-mutant colorectal model with no regrowth after stopping, and nearly doubled survival in a PD-1-cold lung model — with an immune mechanism story that explains why DCI and checkpoint blockade may be natural partners.
IMCRImmunocoreReleaseImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma → BD updateSummary on the 8-K
IMCRImmunocoreReleaseImmunocore reports third quarter financial results and provides a business update → BD updateSummary on the 8-K
IMCRImmunocore8-KCurrent report: results of operations · EX-99.1 → BD updateTEBE-AM's OS readout just slipped to Q2 2027 — the fourth milestone re-date on the most important catalyst in the company — while fresh SITC data show the KIMMTRAK + brenetafusp combination produced a 70% two-year OS rate in 17 first-line mUM patients, and Q3 revenue printed its first nominal year-over-year decline.
IMCRImmunocore10-QQuarterly report → BD updateSummary on the 8-K
HURATuHURA Biosciences8-KCurrent report: debt / obligation
HROWHarrowSCHEDULE 13G/A13G amendment
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GUTSFractyl HealthReleaseFractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
GUTSFractyl Health8-KCurrent report: officer / director change
GOSSGossamer BioSCHEDULE 13G/A13G amendment
GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
EYPTEyePointReleaseEyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
ETONEton PharmaceuticalsSCHEDULE 13G/A13G amendment
ENTXEntera BioReleaseEntera Announces Third Quarter 2026 Financial Results and Business Updates
ENTXEntera Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ENTXEntera Bio10-QQuarterly report
DTILPrecision Biosciences8-KCurrent report: other events · EX-99.1
DTILPrecision Biosciences424B5Prospectus supplement (offering)
CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
CRVOCervoMed10-QQuarterly report → BD update
CMPXCompass TherapeuticsReleaseCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
CGONCG OncologyReleaseCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-K
CGONCG Oncology8-KCurrent report: results of operations · EX-99.1 → BD updatePIVOT-006 Phase 3 topline is now "November 2026" — the Market Expander readout is weeks, not quarters, away — while ANI has escalated to the Delaware Supreme Court, introducing a wrinkle I called "mostly resolved." The stock surged 17.3% on today's Q3 print.
CGONCG Oncology10-QQuarterly report → BD updateSummary on the 8-K
CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 → BD updateSummary on the 8-K
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateNANETS data reveals a sharper enrichment strategy for bamzireotide's Phase 3: SSTR2+ GEP-NET patients show 37–47% ORR and 75% PFS at 18 months, well above Lutathera's labeled benchmarks, with an End-of-Phase 2 FDA meeting now targeted for Q1 2027 — a meaningful step forward on the registration path I've been tracking all year.
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateSummary on the 8-K
CADLCandel TherapeuticsReleaseCandel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
CABACabaletta BioSCHEDULE 13G/A13G amendment
CABACabaletta BioSCHEDULE 13G/A13G amendment
BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026via aggregator
ALLOAllogene Therapeutics10-QQuarterly report → BD updateThe Q3 10-Q lands with three things subscribers need to know before Sunday: Cellectis just announced it's pivoting away from ex vivo CAR-T — the company that makes the TALEN scissors Allogene rents for cema-cel is now openly de-emphasizing the business — and Allogene is already hunting for alternative supply. Meanwhile, the ALLO-329 autoimmune data drops at ACR on November 9, the "autoimmune call option" I've been tracking all year. And Q3 burn on cema-cel alone jumped to $14M external, signaling manufacturing reactivation is real — and expensive.
ALDXAldeyra TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ACRVAcrivon TherapeuticsReleaseAcrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB → BD updateSummary on the 8-K
ACRVAcrivon Therapeutics8-KCurrent report: other events · EX-99.1 → BD updateAcrivon just bought a Phase 2-ready JAK1 inhibitor from Sweden's Aqilion AB, paying undisclosed cash with no future milestone or royalty obligations — and in the process formally declared immunology & inflammation a second strategic pillar alongside oncology. The AP3 platform's ability to characterize pathway activity without relying on genetic mutations may be even better suited to autoimmune disease than cancer.

Thursday, November 5191

ZBIOZenas BioPharmaSCHEDULE 13G/A13G amendment
ZBIOZenas BioPharmaReleaseZenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
ZBIOZenas BioPharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateNew OLE data shows 93% of patients remain flare-free at 12 months and obexelimab's B-cell brake can be released for vaccination — directly answering the reversibility and infection-risk questions — while the Q3 burn rate accelerates to ~$108M/quarter, SunStone inches closer, and the EMA clock starts ticking.
ZBIOZenas BioPharma10-QQuarterly report → BD updateSummary on the 8-K
XERSXeris BiopharmaReleaseXeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights → BD updateSummary on the 8-K
XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1 → BD updateRecorlev just printed $71.5M in Q3 (+93% YoY), Xeris raised 2030 revenue guidance to >$1B, and the stock surged 25% on the earnings release — the cash engine is compounding faster than anyone (including me) modeled.
XERSXeris Biopharma10-QQuarterly report → BD updateSummary on the 8-K
XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
VYGRVoyager TherapeuticsReleaseVoyager Reports Third Quarter 2026 Financial and Operating ResultsSummary on the 8-K
VYGRVoyager Therapeutics8-KCurrent report: acquisition / disposition · EX-99.1Voyager's Q3 print lands with $132.1M cash, a fully confirmed Q4 VY7523 PET readout, and VY1706 dosing on a "pending enrollment" clock — while the ATM is being worked below $3.50 and the stock now trades at a ~19% discount to cash.
VYGRVoyager Therapeutics10-QQuarterly reportSummary on the 8-K
VTVTvTv TherapeuticsReleasevTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSummary on the 8-K
VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1vTv's Q3 print arrives with VTVT down ~28% from early October — the stock's slide predates tonight's release, and three of the most watched variables (ATM, cash runway, timeline) are mostly holding, though a CFO 10b5-1 plan and a quiet G42 timeline slip deserve attention.
VTVTvTv Therapeutics10-QQuarterly reportSummary on the 8-K
VSTMVerastemS-8Employee plan registration
VSTMVerastemS-3ASRAutomatic shelf registration
VSTMVerastemReleaseVerastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
VSTMVerastem8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
VSTMVerastem10-QQuarterly report
VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
VORVor BiopharmaSCHEDULE 13G/A13G amendment
VKTXViking TherapeuticsSCHEDULE 13G/A13G amendment
VIRVir BiotechnologyReleaseVir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference CallTHE BIG ONE is here: ECLIPSE 1 topline data hits the AASLD late-breaking session tomorrow (November 8), with an investor call Monday morning — seven months of buildup lands in the next 72 hours.
VERAVera TherapeuticsReleaseVera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
VERAVera Therapeutics8-KCurrent report: results of operations · EX-99.1TRUTAKNA's first revenue quarter clears $10M on ~700 patient start forms, the ORIGIN 3 data lands in the NEJM, the sBLA is filed, and PIONEER flashes its first signal — yet VERA trades 29% below the December offering price.
VERAVera Therapeutics10-QQuarterly reportSummary on the 8-K
TYRATyra BiosciencesReleaseTyra Biosciences to Participate in Upcoming Investor Conferences
TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
TTRXTurn TherapeuticsReleaseTurn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
TLSATiziana Life SciencesReleaseTiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 5, 2026
TENXTenax TherapeuticsReleaseTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
TENXTenax Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateThe Q3 10-Q revealed a tighter LEVEL-2 enrichment design (+34 m in qualifying patients, 95% CI 15–53), confirmed the Type C meeting is granted, disclosed a securities class-action lawsuit, and showed the August 2024 warrant tranche expired worthless — four developments that collectively update the post-LEVEL bear and watch-list picture.
TENXTenax Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
TECXTectonic TherapeuticReleaseReported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 → BD updateSummary on the 8-K
TECXTectonic Therapeutic8-KCurrent report: acquisition / disposition · EX-99.1 → BD updateAPEX is now inside an 8-week window (end of January 2027), ALPINE dosed its first patient, the ATM accelerated to $22.3M in Q3 alone, and — buried in the 10-Q risk factors — Tectonic itself flags that AZD5462's LUMINARA data "may have affected investor perception of relaxin product candidates," which may help explain the stock's -16.8% slide since the September update.
TECXTectonic Therapeutic10-QQuarterly report → BD updateSummary on the 8-K
STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate DevelopmentsSummary on the 8-K
SRPTSarepta Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 2026 earnings land with the PMO sNDA PDUFA date finally disclosed (February 28, 2027), MAD data for SRP-1003 and SRP-1001 locked in for Q4 2026 with Phase 3 prep already underway, and the balance sheet growing to ~$999M — but a new $62M Catalent take-or-pay charge and a 7.5% session drop heading into the print keep the tension alive.
SRPTSarepta Therapeutics10-QQuarterly reportSummary on the 8-K
SLDBSolid BiosciencesReleaseSolid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
SCYXScynexisS-3Shelf registration → BD updateSummary on the 10-Q
SCYXScynexisReleaseSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 10-Q
SCYXScynexis10-QQuarterly report → BD updateThe Phase 1 SCY-770 gating study is done, the Phase 2 clock is ticking, and SCYX just hired a nephrologist to run R&D — but the stock is down 14% on the day, and the market is reading the S-3 shelf renewal as a capital-raise signal.
SANASana BiotechnologySCHEDULE 13G/A13G amendmentSummary on the 8-K
SANASana BiotechnologyReleaseSana Biotechnology Reports Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
SANASana Biotechnology8-KCurrent report: results of operations · EX-99.1Q3 delivered a GAAP profit (a $63M non-cash accounting gain, not a business transformation), but underneath the headlines: SG293 first-in-human data slipped to 1Q 2027, Mayo passed on its $25M second tranche, and the going-concern flag persists on $121.7M cash — the thesis is tracking but the runway is tighter and the binary catalyst window just moved.
SANASana Biotechnology10-QQuarterly reportSummary on the 8-K
SABSSAB BiotherapeuticsReleaseSAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights → BD updateSummary on the 10-Q
SABSSAB Biotherapeutics10-QQuarterly report → BD updateSAFEGUARD's adult and adolescent cohorts just closed for screening — the enrollment milestone I told you to watch for. The 10-Q also surfaces a quiet internal signal: management's "probability of survival" assumption jumped from 57.5% to 70.0% in a single quarter.
RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
RNACCartesian TherapeuticsReleaseCartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 earnings confirm the AURORA 1Q27 readout and mid-2027 BLA are on track, but quarterly burn has accelerated to ~$98M annualized and the WestGene in vivo trial hasn't launched yet — with the K2HV covenant clock now five months away, the execution margin is tighter than it looked in August.
RNACCartesian Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsSummary on the 10-Q
QNRXQuoin Pharmaceuticals10-QQuarterly reportThe going-concern flag that I quoted verbatim in every QNRX post is gone from the Q3 10-Q — replaced by an affirmative one-year liquidity statement — while $33.2M in cash and investments sits on the balance sheet and a peer-reviewed case report extends the durability data to 21 months.
PTGXProtagonist TherapeuticsReleaseProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Updatevia aggregator→ BD updateSummary on the 8-K
PTGXProtagonist Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateQ3 2026 earnings land after the close: ICOTYDE royalties go undisclosed for a second consecutive full commercial quarter, PN-477sc delivers positive Phase 1 SAD data prompting a strategic pivot to the oral program, and cash prints at $834.6M — confirming the Q4 timing gap I flagged in September.
PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Participate in Upcoming Conferences in November
PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study InitiationSummary on the 8-K
PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q lands a going-concern flag and a Nasdaq minimum-bid-price warning (21 of 30 consecutive days already below $1.00) while cash falls to $10.6M — the death-by-a-thousand-warrants thesis just got a formal auditor co-sign, with an FDA response due by end of November as the only potential escape valve.
PHIOPhio Pharmaceuticals10-QQuarterly reportSummary on the 8-K
PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
PCSAProcessa Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings landed this morning with MAGNITUDE-2 enrollment complete (exceeding its target), a new CMO aboard, and a $127.5M net loss that includes a $10.4M non-cash investment writedown — the market sold the print −9.8%, likely misreading the headline; here's what actually changed and what didn't.
NTLAIntellia Therapeutics10-QQuarterly reportSummary on the 8-K
NRXPNRX PharmaceuticalsDEFA14AProxy soliciting material
NRXPNRX PharmaceuticalsDEF 14AProxy statement
NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
NRIXNurix TherapeuticsReleaseNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
NKTXNkartaReleaseNkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateSummary on the 8-K
NKTXNkarta8-KCurrent report: results of operations · EX-99.1Three days before Nkarta's first NKX019 efficacy readout at ACR, the Q3 10-Q reveals burn accelerating to $33.3M/quarter, cash down to $216M, and a board member resigning — while the stock's -9.2% session move on the filing day suggests the market may already be reading the abstract tea leaves.
NKTXNkarta10-QQuarterly reportSummary on the 8-K
NBPNovaBridge BiosciencesSCHEDULE 13D/A13D amendment
NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
MESOMesoblastReleaseUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinarvia aggregator
LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
LGVNLongeveronSCHEDULE 13G/A13G amendment
LGVNLongeveron8-KCurrent report: officer / director change
LENZLENZ TherapeuticsSCHEDULE 13G/A13G amendment
LEGNLegend BiotechSCHEDULE 13G/A13G amendment
LCTXLineage Cell TherapeuticsReleaseLineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
LBRXLB PharmaceuticalsReleaseLB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
LBRXLB Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateLBRX's Q3 10-Q checks every box on my watch list: $403.8M in cash (at the top of my estimate), NOVA-2 enrollment "progressing strongly" with 1H 2027 readout intact, and two new senior hires filling the leadership gaps that were the clearest near-term bear flags.
LBRXLB Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
KZIAKazia TherapeuticsReleaseKazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
KYTXKyverna TherapeuticsReleaseKyverna Therapeutics to Present at the Jefferies London Healthcare Conference
KROSKeros TherapeuticsReleaseKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results → BD update
KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 → BD update
KROSKeros Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD update
KROSKeros Therapeutics10-QQuarterly report → BD update
KAPAKairos PharmaReleaseKairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
JANXJanux TherapeuticsReleaseJanux Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsSummary on the 8-K
JANXJanux Therapeutics8-KCurrent report: results of operations · EX-99.1Four days before Janux presents the first clinical data from the ARM platform (JANX011), the Q3 release drops a new mechanism disclosure: the drug selectively engages a specific T cell subset (TRBV6-expressing) rather than broad CD3+ activation — a detail that completely reframes what readers should be watching for on November 9.
JANXJanux Therapeutics10-QQuarterly reportSummary on the 8-K
IRONDisc MedicineReleasePivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA dSummary on the 8-K
IRONDisc Medicine8-KCurrent report: results of operations · EX-99.1Disc's Q3 10-Q is out and the numbers have changed: 45.5M shares outstanding post-offering, ~$1.17B pro forma cash, runway into 2030, and a new ATM replacing Cantor. The balance sheet is the strongest it's ever been—but dilution math and the December 17 patent clock are both worth updating before the FDA resubmission.
IRONDisc Medicine424B5Prospectus supplement (offering)Summary on the 8-K
IRONDisc Medicine10-QQuarterly reportSummary on the 8-K
IRDOpus GeneticsReleaseOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal DiseasesOpus dosed all 11 Cohort 2 participants at the 3x higher BEST1 dose, putting topline data in Q1 2027 and a potential pivotal Phase 3 start in H2 2027 — the "other open question" from September is now closed on the input side.
INMBInmune BioReleaseINmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update → BD updateSummary on the 10-Q
INMBInmune Bio10-QQuarterly report → BD updateQ3 reveals $16.3M cash and a drained Australian rebate well — the non-dilutive buffer that bought time all year is gone — while management guides runway through Q3 2027 and quietly pivots XPro toward a quantum-computing-assisted rare-disease search.
INABIN8bioReleaseIN8bio Reports Third Quarter 2026 Financial Results and Recent Business HighlightsSummary on the 8-K
INABIN8bio8-KCurrent report: results of operations · EX-99.1Q3 puts $14.0M cash against an April 2027 wall, but the hire of a gamma-delta TCE pioneer as SVP of R&D and INB-619's debut in Nature Reviews Drug Discovery signal a company accelerating toward the year-end animal data that could unlock the $20.1M PIPE second tranche — if the listing holds.
INABIN8bio10-QQuarterly reportSummary on the 8-K
IMUXImmunic8-KCurrent report: Reg FD disclosure · EX-99.1
GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesSummary on the 8-K
GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 delivered GLUE's first GAAP-profit quarter on the $50M Novartis milestone, cash is effectively ~$620M when the PsA payment lands, and GEMINI-1 in gout is on the doorstep — but the next-gen NEK7 IND slipped again and the stock fell 5% on the print.
GLUEMonte Rosa Therapeutics10-QQuarterly reportSummary on the 8-K
GHRSGH ResearchSCHEDULE 13G/A13G amendment
GANXGain TherapeuticsReleaseGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
FBIOFortress BiotechReleaseJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
FATEFate TherapeuticsS-3Shelf registration → BD updateSummary on the 8-K
FATEFate TherapeuticsReleaseFate Therapeutics Reports Third Quarter 2026 Financial Results And Business Updates → BD updateSummary on the 8-K
FATEFate Therapeutics8-KCurrent report: material agreement, agreement terminated → BD updateFate's Q3 print confirms the raise I said was inevitable has begun — a fresh $100M ATM with Leerink is live, cash sits at $139.1M (plus a $15M CIRM grant), and the runway guidance nudges to mid-2028; now we know exactly what the dilution trap looks like.
FATEFate Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateSummary on the 8-K
FATEFate Therapeutics424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
FATEFate Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
EYPTEyePointReleaseEyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment → BD update
EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring → BD update
EVMNEvommuneReleaseEvommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
EVMNEvommune8-KCurrent report: Reg FD disclosure · EX-99.1
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal TolerabilitySummary on the 8-K
ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1Eton printed a blowout Q3 — $57.9M revenue, 49% Adjusted EBITDA margin, guidance raised to >$175M — but the ET-700 pilot data delivered a split verdict: excellent tolerability (1/12 AEs vs. 8/12 for GALZIN), underwhelming copper blockade (12% reduction vs. 46%), pushing the program back into reformulation and delaying the >$100M peak-sales catalyst into 2027 or beyond.
ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700Summary on the 8-K
ETONEton Pharmaceuticals10-QQuarterly reportSummary on the 8-K
ELVNEnliven TherapeuticsReleaseEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdateSummary on the 8-K
ELVNEnliven Therapeutics8-KCurrent report: results of operations · EX-99.1Enliven has locked in FDA alignment on the final ENABLE-2 Phase 3 design and is on track to dose the first patient before year-end — clearing the last major setup hurdle the thesis was waiting on, while Q3 spend signals the burn rate is accelerating materially as pivotal infrastructure spins up.
ELVNEnliven Therapeutics10-QQuarterly reportSummary on the 8-K
ELTXElicio TherapeuticsReleaseElicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateElicio's Q3 print extends the cash runway to Q2 2027 — removing the imminent extinction risk flagged in October — while the Q4 2026 Phase 1 combination trial with daraxonrasib remains on track, but going-concern language persists and no partner has materialized.
ELTXElicio Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
DYNDyne TherapeuticsReleaseDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsSummary on the 8-K
DYNDyne Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 burn hit $193.6M as launch prep spending surges 65% YoY; cash sits at $1.134B into Q2 2028, but the BIOSECURE CDMO injunction and new pharma tariff risk add nuance to the supply chain picture heading into the January 21 PDUFA.
DYNDyne Therapeutics10-QQuarterly reportSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure → BD updateSummary on the 8-K
DTILPrecision BiosciencesFWPFree writing prospectus (offering terms)→ BD updateSummary on the 8-K
DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1 → BD updateToday was the day I said to wait for: PBGENE-HBV's AASLD data beat the bar I set, the first DMD patient cleared the 8-week safety window the field was watching, and a $125M offering at $7.75 — backed by named institutional buyers — just retired the dilution trap I called the most dangerous item in the bear case.
DFTXDefinium TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateSummary on the 8-K
CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1 CYTOMX Q3 2026 EARNINGS RELEASE_DRAFT_POST_AC_FOR APPROVALQ3 earnings confirm the dose-selection data readout slips to January 2027, BMS's termination is now on the books, and the stock has cratered 37% since the August Fast Track update — but $348M in cash and an expanding indication footprint say the thesis isn't broken, just delayed.
CTMXCytomX Therapeutics10-QQuarterly reportSummary on the 8-K
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE → BD updateCorvus's Q3 2026 update delivered the first real clinical data since my original deep dive — ALPS Phase 2 initial results show soquelitinib's immune-rebalancing mechanism working in a genetically-confirmed rare disease, while the 2027 catalyst calendar is now tighter and better-defined than ever.
CRVSCorvus Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Third Quarter 2026 Financial Results
CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1
CRBUCaribou Biosciences10-QQuarterly report
COGTCogent BiosciencesReleaseCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsSummary on the 8-K
COGTCogent Biosciences8-KCurrent report: results of operations · EX-99.1With the GIST PDUFA 25 days out, Cogent's Q3 print shows a commercial build burning fast — G&A tripled to $42.1M in a single quarter — but $791M in cash, $108.5M in locked-in CMO commitments, and a first clinical look at the avapritinib-switch data at ASH keep the thesis intact heading into the most consequential month in the company's history.
COGTCogent Biosciences10-QQuarterly reportSummary on the 8-K
CLYMClimb BioSCHEDULE 13G/A13G amendmentSummary on the 8-K
CLYMClimb BioS-3ASRAutomatic shelf registrationSummary on the 8-K
CLYMClimb BioReleaseClimb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 8-K
CLYMClimb Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1Q3 earnings surface three under-the-radar thesis updates: Fidelity emerges at 15% ownership, the ATM drew its first $10.1M at $10.00/share in October, and the Delaware summary-judgment hearing on the $157.5M Acelyrin milestone fight has now been held — with a ruling pending.
CLYMClimb Bio10-QQuarterly reportSummary on the 8-K
CLDXCelldex TherapeuticsS-3ASRAutomatic shelf registrationSummary on the 8-K
CLDXCelldex TherapeuticsReleaseCelldex Reports Third Quarter Financial Results and Provides Corporate UpdateSummary on the 8-K
CLDXCelldex Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASEQ3 earnings confirm the fortress balance sheet is intact at $650.3M through 2028, but the old ATM shelf expired and Celldex immediately refiled a new S-3ASR — and management just teased new barzolvolimab indications by year-end, with the stock sitting below the April offering print.
CLDXCelldex Therapeutics10-QQuarterly reportSummary on the 8-K
CGTXCognition TherapeuticsReleaseCognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business UpdateSummary on the 8-K
CGTXCognition Therapeutics8-KCurrent report: results of operations, listing notice · EX-99.1 EXHIBIT 99.1Nasdaq sent the deficiency letter — CGTX officially has until May 3, 2027 to get back above $1.00. The Q3 print shows the balance sheet is holding up better than feared, but the listing clock is now ticking in writing.
CGTXCognition Therapeutics10-QQuarterly reportSummary on the 8-K
CCCCC4 TherapeuticsReleaseC4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CCCCC4 Therapeutics8-KCurrent report: results of operations · EX-99.1
CCCCC4 Therapeutics10-QQuarterly report
CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
CABACabaletta BioReleaseCabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateSummary on the 8-K
CABACabaletta Bio8-KCurrent report: results of operations · EX-99.1Cabaletta's Q3 earnings reveal a 3Q enrollment slowdown in the myositis registrational cohort — blamed on Novartis/BMS competitor safety events — pushing the BLA submission to 1Q28, while $299.4M in cash buys runway to that date and ACR drops one-year DM durability data this Sunday.
CABACabaletta Bio10-QQuarterly reportSummary on the 8-K
BLTEBelite BioReleaseBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
BIOABioAge LabsReleaseBioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 8-K
BIOABioAge Labs8-KCurrent report: results of operations · EX-99.1QUELL-CV topline is now locked to Q4 2026 — the binary is weeks away — but a new manufacturing risk just appeared in the fine print: BioAge's CDMO WuXi AppTec was placed on the Pentagon's Chinese Military Company list in June 2026, adding supply-chain uncertainty to a thesis that was otherwise tracking cleanly into the readout.
BIOABioAge Labs10-QQuarterly reportSummary on the 8-K
BBOTBridgeBio Oncology Therapeutics8-KCurrent report: officer / director change
APVOAptevo TherapeuticsReleaseAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
ANNXAnnexonSCHEDULE 13G/A13G amendment
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
AMLXAmylyx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1Q3 earnings bring the two things the thesis needed most: Amylyx has signed a definitive manufacturing deal with Bachem Americas and a binding term sheet with Polypeptide Group AG (with a $30M upfront capacity reservation), closing the CMC risk I'd been flagging as the last major overhang — and the stock has quietly given back 30% of its post-LUCIDITY gains, setting up an interesting entry point ahead of the ObesityWeek data presentation on November 15.
AMLXAmylyx Pharmaceuticals10-QQuarterly reportSummary on the 8-K
ALTAltimmuneReleaseAltimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026Summary on the release
ALTAltimmuneReleaseAltimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026The full RECLAIM dataset lands at AASLD on November 9 as a late-breaking oral — the highest-visibility slot the conference offers — and an FDA End-of-Phase 2 meeting for the AUD registrational program is now confirmed for December, making the next six weeks the most catalyst-dense stretch in Altimmune's story since the January BTD print.
ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdateSummary on the 8-K
ALLOAllogene Therapeutics8-KCurrent report: results of operations · EX-99.1ALLO-329's first real-world test in autoimmune disease drops in four days at ACR — the "autoimmune call option" I've been tracking all year is finally cashing out, one way or another. Here's what to watch for in the data, what the Q3 numbers tell us about the runway, and why the stock sitting at $1.09 going into the read is either an opportunity or a warning.
ALDXAldeyra Therapeutics10-QQuarterly report
AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsSummary on the 8-K
AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining HemoglobinSummary on the 8-K
AKBAAkebia Therapeutics8-KCurrent report: results of operations · EX-99.1VOCAL hit its non-inferiority endpoint against ESA, completing the clinical evidence arc — but Vafseo's Q3 revenues collapsed to $14.8M on TDAPA inventory destocking even as patients grew to 11,500, exposing the full brutality of the post-TDAPA price reset that starts January 1.
AKBAAkebia Therapeutics10-QQuarterly reportSummary on the 8-K
AGIOAgios PharmaceuticalsReleaseAgios Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
AGIOAgios Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateAGIO dropped ~10% on Q3 results that actually showed record revenue of $55.4M — the thalassemia launch is accelerating faster than the bear case allowed, with 75% six-month retention, but the market appears to be pricing the REMS/February-label uncertainty and a new R&D headcount cut that acknowledges the cost base problem.
AGIOAgios Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateSummary on the 8-K
ACRSAclaris Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings reveal a third, undisclosed ATM tap in September at ~$5.56/share, pushing the dilution toll to ~30M new shares year-to-date, while runway gets extended to 1H 2029 and the bosakitug ADMIRATION readout is now weeks away.
ACRSAclaris Therapeutics10-QQuarterly reportSummary on the 8-K
ACETAdicet BioReleaseAdicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates → BD updateSummary on the 8-K
ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1 → BD updateAdicet's Q3 10-Q — filed after the close — contains a formal going-concern disclosure and a $100.9M cash balance against ~$79M annualized burn, with the pivotal readout not until 2029. The raise is no longer a risk; it's a schedule.
ACETAdicet Bio10-QQuarterly report → BD updateSummary on the 8-K
ABOSAcumen Pharmaceuticals8-KCurrent report: agreement terminated, exit / restructuring costs

Wednesday, November 4144

XNCRXencorReleaseXencor Reports Third Quarter 2026 Financial ResultsSummary on the 8-K
XNCRXencor8-KCurrent report: results of operations · EX-99.1Q3 delivers net income of $39.4M, year-end cash guidance rises to $480–500M (third consecutive raise), and Xencor cashes out $66.9M of Zenas stock — the balance sheet is stronger than ever as XmAb819 heads toward an FDA accelerated-approval meeting in 1H 2027.
XNCRXencor10-QQuarterly reportSummary on the 8-K
XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 10-Q
XFORX4 Pharmaceuticals10-QQuarterly report → BD updateThe Q3 10-Q finally discloses the K2 covenant structure — a 75%-of-debt cash lock starting Oct 1, 2027 that compresses usable runway ahead of the H1 2028 4WARD readout — while 4STEPS emerges as a new clinical program and WHIM sales tick up for the first time in three quarters.
VRDNViridian TherapeuticsReleaseViridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress → BD updateSummary on the 8-K
VRDNViridian Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateLumvoa's first real revenue quarter prints $24.7M — ahead of what a mid-quarter launch should deliver — and the stock surged 15.5% on the day; the J-code, the Q4 pipeline catalysts, and the royalty math all need a fresh read.
VRDNViridian Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
VIRVir BiotechnologyReleaseVir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
VIRVir Biotechnology8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 earnings land with ECLIPSE 1 now explicitly "this quarter," VIR-5500 earns FDA Fast Track and proof-of-concept status, and the VIR-5818 HER2 data timeline quietly slips on FDA Project Optimus feedback — the platform-generalization test just got delayed.
VIRVir Biotechnology10-QQuarterly report → BD updateSummary on the 8-K
UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
TNGXTango TherapeuticsReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
STROSutro BiopharmaReleaseSutro Biopharma to Participate in Upcoming Investor Conferencesvia aggregator
SNDXSyndax PharmaceuticalsReleaseSyndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026via aggregatorSummary on the release
SNDXSyndax PharmaceuticalsReleaseSyndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026via aggregatorSNDX dropped ~27% today with no company-disclosed catalyst, while Syndax simultaneously announced 19 ASH abstracts including seven oral presentations — first post-transplant maintenance trial data, updated BEAT AML/SAVE frontline combinations, and two menin-resistance mechanism readouts arriving December 12-14.
SMMTSummit TherapeuticsReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026Summary on the 8-K
SMMTSummit Therapeutics8-KCurrent report: results of operations, charter / bylaws / fiscal year, shareholder vote · EX-99.1Summary on the 8-K
SMMTSummit Therapeutics8-KCurrent report: other eventsWith the authorized-share vote cleared today and the PDUFA 10 days out, Summit enters its most consequential window yet — a fortified balance sheet, imminent HARMONi-3 squamous data, and a binary FDA decision all stacking into the same fortnight.
SMMTSummit Therapeutics424B7Prospectus supplementSummary on the 8-K
SMMTSummit Therapeutics10-QQuarterly reportSummary on the 8-K
SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026With the REGAL binary imminent, SELLAS's Plan B just got a lot more real: SLS009 Phase 2 data headed to ASH shows 54–57% ORR in venetoclax-failed, high-risk AML subgroups where historical survival is ~2.5 months — and the safety profile is clean.
SLDBSolid BiosciencesReleaseSolid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business UpdatesSummary on the 10-Q
SLDBSolid Biosciences10-QQuarterly reportThe Q3 10-Q lands weeks before the Type C FDA meeting that decides SGT-003's accelerated approval fate — the binary I've been tracking all year is now imminent, the safety database is holding, and the balance sheet is intact at $348.9M.
SEPNSepterna8-KCurrent report: Reg FD disclosure · EX-99.1
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl SyndromeRYTM ripped 28% today — from the Q3 selloff low of $86.44 back to $110 — on NICE expanding adult BBS reimbursement in England, Wales and Northern Ireland. The move likely reflects more than one day's headline: it's a catch-up to the strong Q3 commercial print combined with a fresh UK payer win that adds real-world coverage to an already-approved indication.
RVMDRevolution MedicinesReleaseRevolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress → BD updateSummary on the 8-K
RVMDRevolution Medicines8-KCurrent report: results of operations · EX-99.1 → BD update$197.6M in RASONQUE net revenue on five weeks of sales, >5,000 patients, >90% covered lives reimbursed — the first commercial print just answered the question the whole Watch List thesis was waiting on.
RVMDRevolution Medicines10-QQuarterly report → BD updateSummary on the 8-K
RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in Londonvia aggregator
RLAYRelay TherapeuticsReleaseRelay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates → BD updateSummary on the 8-K
RLAYRelay Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateRelay's Q3 print — released after the close — brings three thesis-movers: ReDiscover-2 enrollment tracking ~1 year ahead of benchmark (mid-2027 completion), updated ReInspire vascular anomaly data locked in for an ASH oral on December 14 with a same-day regulatory call, and a commercial hire (Shannon Campbell, ex-Merus CCO) signaling Relay is treating launch as a planning reality. The December 14 ASH readout is now the clearest near-term de-risking event in the story.
RLAYRelay Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
RCUSArcus BiosciencesReleaseArcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pi...Summary on the 8-K
RCUSArcus Biosciences8-KCurrent report: results of operations · EX-99.1Q3 earnings confirm the fortress balance sheet now reaches into 2029 post-offering, Arcus named a fifth bispecific partner (Pfizer's tivunatamig), and the PRISM-1 interim analysis in pancreatic cancer is now expected this quarter — a binary catalyst I flagged as a "synthetic-control-arm coin flip" that has been quietly approaching.
RCUSArcus Biosciences10-QQuarterly reportSummary on the 8-K
RAREUltragenyx Pharmaceutical10-QQuarterly reportThe Q3 10-Q puts real numbers on the post-Aspire thesis for the first time: a $43M operating cash draw, ~$750M of pro-forma liquidity once both PRV sales close, and zero gene therapy revenue yet — the launch ramp that determines whether the 2027 profitability target is real is now the only story left to watch.
RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
RAPPRapport Therapeutics10-QQuarterly report
QUREuniQureReleaseuniQure Announces Third Quarter 2026 Financial Results and Provides Company Updatevia aggregatorSummary on the 8-K
QUREuniQure8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q lands with a quietly important reversal: AMT-191 (Fabry) dosing has resumed after the DLT pause, the Genezen CDMO note got restructured at a higher cost, confirmatory-study screening kicks off by year-end, and the motion-to-dismiss deadline in the Scocco class action is today — all while the fortress balance sheet holds at $768.4M.
QUREuniQure10-QQuarterly reportSummary on the 8-K
QTTBQ32 BioReleaseQ32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSummary on the 8-K
QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1Q32 Bio's Q3 10-Q confirms $289.6M in cash, zero ATM usage, and two senior leadership hires that close the organizational gap I flagged — with the FDA end-of-Phase 2 meeting now imminent this quarter and the stock still trading near or slightly below cash value.
QTTBQ32 Bio10-QQuarterly reportSummary on the 8-K
QNRXQuoin PharmaceuticalsEFFECTRegistration effective → BD updateSummary on the 8-K
QNRXQuoin Pharmaceuticals8-KCurrent report: material agreement → BD updateQuoin filed a new $11M at-the-market equity facility with Leerink after the close — just 10 weeks after closing a $30.8M PIPE — adding a continuous dilution spigot to a stock already down 44% from its September high and raising the question of why fresh capital is needed this soon.
QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
PMVPPMV PharmaceuticalsReleasePivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
PCVXVaxcyteReleaseVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
PCVXVaxcyte8-KCurrent report: results of operations · EX-99.1 → BD updateAfter the October OPUS-1 win and $1.1B raise, the Q3 10-Q restores the fortress balance sheet to ~$3.4B pro forma, cuts near-term manufacturing commitments, and quietly escalates the ACIP risk I've been flagging since day one — now acknowledged in Vaxcyte's own risk factors for the first time.
PCVXVaxcyte10-QQuarterly report → BD updateSummary on the 8-K
PCSAProcessa PharmaceuticalsReleaseProcessa Pharmaceuticals Announces Key Leadership AppointmentsSummary on the 8-K
PCSAProcessa Pharmaceuticals8-KCurrent report: officer / director change, other events · EX-99.1 EXHIBIT 99.1PCSA just hired a full C-suite: a COO with 25+ years of biotech ops experience, the scientist who helped *invent* VT-7208 as Head of Research, a seasoned regulatory/development lead, and a business operations chief — completing the institutional-grade team the $200M PIPE demanded to see.
ONCYOncolytics BiotechReleaseTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
OLMAOlema PharmaceuticalsReleaseOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
OKUROnKure TherapeuticsReleaseOnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights → BD updateSummary on the 8-K
OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateThe Q3 10-Q answers the three questions I told you to track: the ATM is still clean (zero shares sold), cash is $163.3M (~$3.27/share, still above the stock price), and PIKture-01 is still missing from every filing with SABCS seven weeks away. Two China-based CMOs are named for the first time, adding a supply-chain risk I could only flag as theoretical before.
OKUROnKure Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
OCGNOcugenReleaseOcugen Provides Business Update with Third Quarter 2026 Financial ResultsSummary on the 8-K
OCGNOcugen8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1Ocugen's Q3 2026 earnings landed with a nearly flat net loss of $3.6M — dramatically better than the year-ago $20M — driven by a $16.6M derivative liability mark-down as the stock slid from convertible pricing levels; the December 22 authorized-share vote is confirmed; and the investor deck breaks out new OCU400 Phase 1/2 data showing 71.4% of the 7-patient ITT cohort projected to clear the Phase 3 response bar.
OCGNOcugen10-QQuarterly reportSummary on the 8-K
NVCTNuvectis PharmaReleaseNuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlightsvia aggregator→ BD updateSummary on the 8-K
NVCTNuvectis Pharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateThe Q3 report brings the first confirmation that FDA discussions on a U.S. ciprocopan path are "well underway," but the NXP900 Phase 1b combination update has quietly slipped to 1H 2027 — and the ATM's $37M single-fund placement finally starts to answer the institutional-sponsorship question.
NVCTNuvectis Pharma10-QQuarterly report → BD updateSummary on the 8-K
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)MAGNITUDE-2 is fully enrolled — the ATTRv-PN Phase 3 clock is now running, adding a second near-term readout to a catalyst stack already anchored by the March 10, 2027 lonvo-z PDUFA date.
NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results → BD updateSummary on the 8-K
NAMSNewAmsterdam Pharma8-KCurrent report · EX-99.1 → BD updateWith the PREVAIL interim event count on track for Q4 2026 and a DSMB recommendation landing in Q1 2027, the binary I've been tracking is now weeks away — and today's Q3 update confirms $643.1M in cash, a new Phase 2b Alzheimer's trial (SPINOZA), and a RUBENS readout before year-end.
NAMSNewAmsterdam Pharma10-QQuarterly report → BD updateSummary on the 8-K
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
MLYSMineralys Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1 → BD updateQ3 earnings confirm the launch-cost ramp is steeper than prior quarters ($37.4M G&A vs. $9.7M a year ago), the Tanabe IP transfer is finally closed, RA Capital's board representative just resigned, and a 100%-tariff risk on drug imports is disclosed for the first time—all with 7 weeks to the PDUFA.
MLYSMineralys Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
MLTXMoonLake ImmunotherapeuticsReleaseMoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update → BD updateSummary on the 8-K
MLTXMoonLake Immunotherapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateMoonLake submitted the HS BLA on September 30 and will hear on acceptance by end of November — the thesis-defining unlock — but the Q3 10-Q reveals the Tranche 4 $50M quietly lapsed into the discretionary Tranche 6 and a $17M MHKDG milestone is already accrued, tightening the balance sheet further than the "$498.5M / mid-2028 runway" headline implies.
MLTXMoonLake Immunotherapeutics10-QQuarterly report → BD updateSummary on the 8-K
MDNAFMedicenna TherapeuticsReleaseMedicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion LeadersABILITY-1 enrollment is complete at n=152, the oral at SITC lands November 7 with updated ORR data already in the release (36% mono / 43% combo in key cohorts), and a KOL webinar follows November 10 — the Q4 data catalyst I've been tracking all year is now days away.
MBRXMoleculin BiotechReleaseMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingSummary on the 8-K
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1An ASH abstract acceptance just sent MBRX up 51% from the last-update close — the same n=45 interim data I've already dissected, now on a December poster, with the equity capital structure still a ratchet trap and cash cliff unchanged.
LXEOLexeo TherapeuticsEFFECTRegistration effective
LRMRLarimar TherapeuticsReleaseLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
LEGNLegend BiotechReleaseLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
KURAKura OncologyReleaseKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
IRONDisc MedicineReleaseTwo oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (
INSMInsmedReleaseInsmed to Present at November and December 2026 Investor Conferences
IMRXImmuneeringReleaseImmuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
IMRXImmuneeringReleaseImmuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
IMNMImmunomeReleaseImmunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026via aggregator→ BD updateIM-1021 delivers a 53% ORR (64% in DLBCL) across all dose levels in heavily pretreated B-NHL patients — the first human proof that the HC74 TOP1i payload engine works, the exact catalyst I said could convert optionality into an asset.
IMMXImmix BiopharmaReleaseImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IBRXImmunityBioReleaseImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
HURATuHURA BiosciencesReleaseTuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
HRMYHarmony BiosciencesReleaseHarmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting → BD updateSummary on the 8-K
HRMYHarmony Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD updateHarmony's Q3 earnings and BP-205 MAD data land on the same day — the first repeated-dose safety look at its orexin agonist clears the critical liver/cardiac bar, while WAKIX hits $269M (+12%) and a new legal calendar accelerates the patent-cliff timeline into early 2027.
HRMYHarmony Biosciences10-QQuarterly report → BD updateSummary on the 8-K
GPCRStructure TherapeuticsReleaseStructure Therapeutics to Participate in the Jefferies Global Healthcare Conference
GNLXGeneluxSCHEDULE 13G/A13G amendment
GERNGeronReleaseGeron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights → BD updateSummary on the 8-K
GERNGeronReleaseGeron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 → BD updateSummary on the 8-K
GERNGeron8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 2026 delivered GERN's first clean operating profit ($5.8M) post-IMpactMF collapse, cash grew sequentially to $339M, and demand accelerated 10% QoQ to 1,700 accounts — but the securities class action survived a motion to dismiss and is now in discovery, adding a new and unpriced tail risk to the already-levered balance sheet.
GERNGeron10-QQuarterly report → BD updateSummary on the 8-K
FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
EYPTEyePointSCHEDULE 13G/A13G amendment
EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
EWTXEdgewise Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateEdgewise's Q3 print confirmed a better-than-estimated tax bill ($155M vs. ~$226M feared), leaving $1.74B in cash — but GRAND CANYON failed on November 3, wiping the $100–200M Becker milestone off the table, while EDG-15400 quietly dosed its first HFpEF patient, closing the Phase 1 disclosure gap I flagged in the original writeup.
EWTXEdgewise Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
EVMNEvommuneReleaseEvommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals → BD updateSummary on the 8-K
EVMNEvommuneReleaseEvommune Announces $30 Million Private Placement → BD updateSummary on the 8-K
EVMNEvommune8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 → BD updateEvommune just reloaded the pipeline with a licensed VAV1 molecular glue degrader (EVO570) showing ~20× greater preclinical potency than Novartis's MRT-6160, backed by a $30M PIPE at current prices from OrbiMed, Adage, and Balyasny — a meaningful signal that institutional money is re-engaging the story after two EVO756 failures.
EVMNEvommune424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
ERASErascaReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences
ELTXElicio TherapeuticsReleaseElicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for HematoThe ALPS catalyst I flagged for late 2026 just landed: soquelitinib's NIH-led Phase 2 delivered one-year safety and efficacy data in a genetically confirmed immune disorder — zero severe adverse events, all three patients off background steroids — providing the kind of mechanism validation the thesis called for ahead of the pivotal 1H 2027 AD readout.
CRBUCaribou BiosciencesReleaseCaribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
CLYMClimb BioReleaseClimb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
CLRBCellectar BiosciencesReleaseCellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
CLNNCleneReleaseClene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsSummary on the 8-K
CLNNClene8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1The Q3 10-Q reveals $9.9M cash, a ~$13M current debt wall, a fresh $7.2M NIH subaward, and management's first explicit disclosure that NDA acceptance could trigger $6.7M–$7.8M in warrant cash — all landing the same morning the stock jumped +8.8%.
CLNNClene10-QQuarterly reportSummary on the 8-K
CLDXCelldex TherapeuticsReleaseCelldex to Present at Upcoming Investor Conferences
CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual MeetingSummary on the 8-K
CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1The CLN-049 Phase 1 dataset — 87 patients, optimized dosing at 6 and 12 µg/kg — landed this morning and the stock dropped 20.7%, but the headline CRc compression vs. earlier data may be less damning than the tape suggests when you read the regimen change that drove it.
BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual MeetingThe BEACON risto-cel data earns an oral slot at ASH and lands in the press program — with patient-reported outcomes data showing real-world functional improvements now added to the efficacy story, and the BLA timeline locked to year-end 2026.
BCRXBiocryst PharmaceuticalsReleaseBioCryst Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
BCRXBiocryst PharmaceuticalsReleaseBioCryst to Present at Upcoming Investor Conferences → BD updateSummary on the 8-K
BCRXBiocryst Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE → BD updateBioCryst's Q3 print cleared the CareMed transition risk and accelerated the OMERS royalty-cap timeline, but investors should understand that headline ORLADEYO revenue was flattered by a mid-teens inventory build — the underlying business is tracking, not accelerating.
BCRXBiocryst Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2026
ARVNArvinasReleaseArvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hemat
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics to Present at Jefferies Global Healthcare Conference in LondonAN2 Therapeutics has nominated AN2-504661 — a novel oral ENPP1 inhibitor — as a development candidate for hypophosphatasia (HPP), delivering on the catalyst the prior writeup flagged as a guided end-2026 milestone and adding a fourth rare-disease leg to the platform.
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)Summary on the release
ANIXAnixa BiosciencesReleaseNOV 04, 2026 8:35 AM EST Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026↗ Robert Wenham, M.D., Chair of the G
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
AGIOAgios PharmaceuticalsReleaseAgios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
ADMAAdma BiologicsReleaseADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
ADMAAdma Biologics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1 → BD updateADMA's Q3 2026 print shows ASCENIV at $124.7M (+31% YoY, +21% sequentially), gross margin of 71%, and $105M of nine-month operating cash flow — clearing another gate on the path from Watch List toward conviction, while FDA pre-IND feedback on SG-001 adds a first pipeline milestone.
ADMAAdma Biologics10-QQuarterly report → BD updateSummary on the 8-K
ADCTADC TherapeuticsReleaseADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program → BD updateSummary on the 8-K
ADCTADC Therapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateThe LOTIS-7 abstract data the entire thesis has been waiting for arrived after the close: 88.7% ORR and 75.3% CR across 97 evaluable r/r DLBCL patients, with responses deepening over time and median PFS not reached — and critically, a safety profile that looks far cleaner than LOTIS-5's fatal-infection disaster.
ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS TO PRESENT PROMISING PRECLINICAL DATA DEMONSTRATING ANTITUMOR AND IMMUNE ACTIVATION ACTIVITY OF ELRAGLUSIB ORAL TABLET IN ADVANCED MELANOMA MODELS AT ENA 2026
ACRVAcrivon TherapeuticsReleaseAcrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
ACIUAC ImmuneReleaseAC Immune Third Quarter 2026 Financial and Corporate Update → BD updateSummary on the 6-K
ACIUAC Immune6-KForeign issuer report · EX-99.1 → BD updateAC Immune's Q3 update quietly extends cash runway to Q1 2028, pushes the hsCRP readout to H1 2027, and declares a Morphomer a-syn lead candidate — the balance sheet got better, the near-term catalyst calendar shifted, and the stock moved +9.6% on the news.

Tuesday, November 380

ZURAZura BioEFFECTRegistration effective
XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
XENEXenon PharmaceuticalsReleaseXenon to Present at Upcoming Investor Conferences
VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
TNGXTango TherapeuticsReleaseTango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
SYRESpyre TherapeuticsReleaseSpyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
SYRESpyre Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateSKYWAY's final two sub-studies (PsA and axSpA) missed their primary endpoints, closing the door on rheumatic diseases for SPY072 entirely — while SKYLINE Part B accelerates toward a Q3 2027 combination readout and the fortress balance sheet grows to $1.47B pro forma.
SYRESpyre Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
STOKStoke TherapeuticsReleaseStoke Therapeutics to Present at Upcoming Investor Conferences in November
STOKStoke Therapeutics10-QQuarterly report
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update → BD updateSummary on the 8-K
RYTMRhythm Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 delivered another strong commercial beat ($92.1M, +29% QoQ, >700 PSFs) — but the market is selling the news because Rhythm simultaneously agreed to pay LG Chem $350M over four years to slash its bivamelagon royalty, financed by a new $750M term loan that adds meaningful leverage to a company still burning cash.
RYTMRhythm Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026via aggregator
RAREUltragenyx PharmaceuticalReleaseUltragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 → BD updateSummary on the 8-K
RAREUltragenyx Pharmaceutical8-KCurrent report: acquisition / disposition, results of operations, exit / restructuring costs · EX-99.1 → BD updateQ3 2026 earnings confirm the transformation is real: operating cash burn collapsed to $43M for the quarter, a second 20% workforce reduction is underway, UX701 is terminated, Angelman is officially wound down, and R&D spending is being cut in half — but 2027 GAAP profitability is reaffirmed and the balance sheet now has ~$750M+ of cash plus PRV proceeds incoming.
PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
ORKAOruka TherapeuticsReleaseOruka Therapeutics to Participate in Multiple Upcoming Conferences
ORICOric PharmaceuticalsReleaseORIC® Pharmaceuticals to Participate in Upcoming Investor Conferencesvia aggregator
OCSOculis HoldingReleaseOculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts → BD updateSummary on the 6-K
OCSOculis Holding6-KForeign issuer report · EX-99.1 → BD updatePREDICT-1 enrollment is complete at 176 patients with topline data due around year-end, while new ACUITY biomarker data, two senior neurology hires, and an expanded $125M ATM arrive as OCS trades at $7.63 — a 40% slide since the August update — compressing the EV to a level where the speculative math looks different.
OCSOculis Holding424B5Prospectus supplement (offering)→ BD updateSummary on the 6-K
NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 → BD updateSummary on the 8-K
NRIXNurix Therapeutics8-KCurrent report: other events → BD updateSanofi has terminated the Phase 1 trial of SAR448272, its STAT6 degrader developed under the Nurix collaboration — permanently wiping ~$455M in future milestones from the "free carry" partnered pipeline I've been tracking since April. The reaction hasn't hit the tape yet, but the thesis needs a recalibration.
NGNENeurogeneReleaseNeurogene to Participate in Upcoming Investor Conferences
NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
MLYSMineralys TherapeuticsReleaseMineralys Therapeutics to Participate in Upcoming Investor Conferences
MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
MESOMesoblast6-KForeign issuer report · EX-99.1
MAZEMaze TherapeuticsReleaseMaze Therapeutics to Participate in Upcoming Investor Conferences
LQDALiquidiaReleaseLiquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
LENZLENZ Therapeutics10-QQuarterly report
KURAKura OncologyReleaseKura Oncology to Report Third Quarter Financial Results on November 10
KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)→ BD updateThe FDA has cleared an IND for a randomized, placebo-controlled Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas — a 80,000-patient indication with zero approved systemic therapies, and the exact "label-expansion seed" I flagged in June.
KAPAKairos PharmaReleaseKairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
KAPAKairos Pharma8-KCurrent report: material agreement, other events · EX-99.1
JBIOJade BiosciencesReleaseJade Biosciences to Participate in Upcoming Conferences
IRDOpus GeneticsReleaseOpus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
IDYAIDEAYA BiosciencesS-8Employee plan registration → BD updateSummary on the 8-K
IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update → BD updateSummary on the 8-K
IDYAIDEAYA Biosciences8-KCurrent report: results of operations · EX-99.1 → BD updateOptimUM-010 is formally dead — IDEAYA just canceled the neoadjuvant Phase 3, banking $100-125M in savings to fund two IDE849 registrational trials (SCLC and NEC). The Q3 10-Q confirms the burn is accelerating and the SCLC bet is scaling fast.
IDYAIDEAYA Biosciences10-QQuarterly report → BD updateSummary on the 8-K
HELPHelus PharmaReleaseHelus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
GERNGeronReleaseGeron Corporation to Participate in the Stifel 2026 Healthcare Conference
FHTXFoghorn TherapeuticsReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
EXELExelixisReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ERASErascaReleaseErasca to Present at Upcoming Conferences in November
DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment → BD updateSummary on the 8-K
DTILPrecision BiosciencesReleasePrecision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update → BD updateSummary on the 8-K
DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1 → BD updateQ3 numbers confirm the ATM is open again and cash is burning faster than the Q2 "discipline" signal suggested — but the bigger story is that new ELIMINATE-B data drops publicly on November 5 and hits the podium at AASLD on November 8, making this the most time-sensitive update since the August first-dosing post.
DTILPrecision Biosciences10-QQuarterly report → BD updateSummary on the 8-K
DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences
CTNMContineum Therapeutics8-KCurrent report: results of operations · EX-99.1
CTNMContineum Therapeutics10-QQuarterly report
CRDLCardiol TherapeuticsSUPPLSUPPL → BD updateSummary on the 6-K
CRDLCardiol TherapeuticsReleaseCardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC → BD updateSummary on the 6-K
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED NOVEMBER 3, 2026 → BD updateSummary on the 6-K
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1 → BD updateThe ATM dilution machine I warned about in September is now live: Cardiol activated a US$75M at-the-market offering through Jefferies, the exact scenario I flagged as a downside trigger — and the stock has already shed ~41% since the last update.
CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights → BD updateSummary on the 8-K
CMPSCOMPASS Pathways8-KCurrent report: results of operations · EX-99.1 → BD updateThe NDA is days away and $444M in cash funds the company into 2028 — so why is CMPS down 43% since September? The Q3 report answers the question, and the thesis is intact.
CMPSCOMPASS Pathways10-QQuarterly report → BD updateSummary on the 8-K
CMMBChemomab Therapeutics6-KForeign issuer report
CGENCompugenReleaseCompugen to Participate in November Investor Conferences
CCCCC4 TherapeuticsReleaseC4 Therapeutics to Participate in Upcoming November Investor Conferences
CAPRCapricor TherapeuticsReleaseCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing PortfolioSummary on the 8-K
BEAMBeam Therapeutics8-KCurrent report: results of operations · EX-99.1Q3 earnings arrive as BEAM enters its most critical execution quarter: risto-cel BLA filing expected by year-end, BEAM-302 pivotal cohort dosing set to complete 1H 2027, and $1.0B on hand — but the runway math is now explicitly milestone-gated, and the Apellis collaboration has quietly unraveled.
BEAMBeam Therapeutics10-QQuarterly reportSummary on the 8-K
BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026via aggregator
AXSMAxsome TherapeuticsReleaseAxsome Therapeutics to Participate in Upcoming Investor Conferences
ARVNArvinasS-3Shelf registration → BD updateSummary on the 8-K
ARVNArvinasReleaseArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update → BD updateSummary on the 8-K
ARVNArvinas8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD updateQ3 earnings confirm ARV-6723 is now dosing patients, ARV-393 data lands at ASH in December, and $558.9M cash holds the fort — but the stock is at $7.09, the CMO seat is still empty, and a fresh $400M shelf registration raises dilution awareness heading into the catalyst window.
ARVNArvinas10-QQuarterly report → BD updateSummary on the 8-K
ARDXArdelyxReleaseArdelyx Reports Third Quarter 2026 Financial Results and Provides Business Update → BD update
ARDXArdelyxReleaseArdelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation → BD update
ARDXArdelyx8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 → BD update
ARDXArdelyx10-QQuarterly report → BD update
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
ALLOAllogene TherapeuticsReleaseAllogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
ADCTADC TherapeuticsS-4Merger registration
ADCTADC TherapeuticsReleaseADC Therapeutics to Present at November Investor Conferences

Monday, November 270

XERSXeris BiopharmaReleaseXeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
XERSXeris Biopharma8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
XENEXenon PharmaceuticalsReleaseXenon to Report Q3 2026 Financial Results on November 9, 2026
VSTMVerastemReleaseVerastem Oncology to Participate in Upcoming November Investor Conferences
VIRVir BiotechnologyReleaseVir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
VERAVera TherapeuticsReleaseVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
TVTXTravere TherapeuticsReleaseTravere Therapeutics Reports Third Quarter 2026 Financial Results → BD updateSummary on the 8-K
TVTXTravere Therapeutics8-KCurrent report: results of operations · EX-99.1 → BD updateFILSPARI hit $200M in a single quarter (+120% YoY) — another record print — while the IgAN patent finally issued and hit the Orange Book, the BIOSECURE injunction gave the API supplier a temporary reprieve, and ASN data reinforced the dual-blockade thesis one more time.
TVTXTravere Therapeutics10-QQuarterly report → BD updateSummary on the 8-K
TLSATiziana Life SciencesReleaseTiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis → BD updateSummary on the 6-K
TLSATiziana Life Sciences6-K/AForeign issuer report (amended)→ BD updateSummary on the 6-K
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 2, 2026 → BD updateINFORM-MS hit its primary PET endpoint (p=0.0168) and safety primary — the first randomized, placebo-controlled evidence that a nasal anti-CD3 antibody reduces microglial activation in the brain. The science score just moved, but the stock is down 16% on the day, likely pricing in the near-certain dilutive raise that was always going to follow this result.
TGTXTg TherapeuticsReleaseTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
SPRBSpruce BiosciencesReleaseSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer - Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -→ BD updateSummary on the 8-K
SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update – Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj ® (revumenib) net revenu → BD updateSummary on the 8-K
SNDXSyndax Pharmaceuticals8-KCurrent report: results of operations, officer / director change · EX-99.1 → BD updateRevuforj's Q3 print directly tests the NPM1m share-erosion tripwire I flagged in the writeup — and it holds: new patients accelerated 20% quarter-over-quarter with management claiming dominant share across all age groups, while the CFO transition adds a new strategic signal to decode.
SNDXSyndax Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
SIONSionna TherapeuticsReleaseSionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
RXRXRecursion PharmaceuticalsReleaseRecursion Appoints Fred Hassan as Chair of the Board → BD updateSummary on the 8-K
RXRXRecursion PharmaceuticalsReleaseNew Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps → BD updateSummary on the 8-K
RXRXRecursion PharmaceuticalsReleaseRecursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred → BD updateSummary on the 8-K
RXRXRecursion Pharmaceuticals8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1 → BD updateThe CGA-IGC plenary I called a must-watch catalyst has landed — REC-4881's expanded TUPELO data strengthened across every GI compartment, and REC-1245 produced the first confirmed efficacy from a Recursion-designed molecule. The one watch-list trigger still outstanding: the FDA endpoint decision.
RXRXRecursion Pharmaceuticals10-QQuarterly report → BD updateSummary on the 8-K
RNTXRein TherapeuticsReleaseRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
RLAYRelay TherapeuticsReleaseRelay Therapeutics to Participate in Three Upcoming Investor Conferences in November
RCUSArcus BiosciencesReleaseArcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2...
QUREuniQureReleaseuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Diseasevia aggregator→ BD updateSummary on the 8-K
QUREuniQure8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1 → BD updateThe FDA accepted the AMT-130 BLA under Priority Review with a May 1, 2027 PDUFA date — the exact binary I told readers to wait for in September — and the stock is inexplicably down 7.5% on the news, creating one of the more interesting re-entry setups this story has thrown off.
OLMAOlema PharmaceuticalsReleaseOlema Oncology to Participate in Upcoming Investor Conferences
OCSOculis HoldingReleaseOculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology InnovationOculis hired Roche's former Head of Integrative Neuroscience as CSO — the most credible organizational signal yet that the Privosegtor neuro-axonal franchise is a real program, not a slide deck, arriving as the stock hits new post-DIAMOND lows.
NVCTNuvectis PharmaReleaseNuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026via aggregator
NRXPNRX Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
NRSNNeuroSense TherapeuticsReleaseNeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data → BD updateSummary on the 6-K
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED NOVEMBER 2, 2026 → BD updateThe Canadian NDS deadline slipped three months to March 2027 — extending the one near-term catalyst into the Nasdaq Panel's maximum window — while new NfL biomarker data from PARADIGM provides a genuine, if incremental, scientific positive. The stock is down 38.6% week-over-week and now trading well below the $5M immediate-delisting floor.
MISTMilestone PharmaceuticalsReleaseNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in NovemberLX2006's 36-month follow-up data — being presented at ICAR this week — show sustained and *deepening* neurological benefit over time, directly answering the durability question I've called the thesis's most stubborn unknown since the December deep dive.company site may be offline after the acquisition
LENZLENZ TherapeuticsSCHEDULE 13D/A13D amendment → BD updateRA Capital — the "elite, science-literate" anchor I cited as a core conviction signal — sold its entire LENZ equity stake across three days this week, dropping from ~15.5% to 0.2% (warrants only). That changes the bull case in a way subscribers need to hear.
KZIAKazia TherapeuticsReleaseKazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
KZIAKazia TherapeuticsNT 20-FNT 20-F
JANXJanux TherapeuticsReleaseJanux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy VolunteersThe JANX011 autoimmune lottery ticket is about to pay out — or not. Janux just announced a November 9 virtual event presenting the initial Phase 1 healthy-volunteer data, including safety, PK, and B-cell pharmacodynamics: the exact readout the thesis has been building toward.
IRONDisc MedicineReleaseWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
IONSIonis PharmaceuticalsReleaseIonis to hold third quarter 2026 financial results webcast
INKTMiNK TherapeuticsReleaseMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
IMUXImmunicSCHEDULE 13G/A13G amendment
IMUXImmunicReleaseImmunic to Participate in Investor Conferences in November
IMNMImmunomeReleaseImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
HROWHarrowReleaseHarrow Launches HarrowRx Platform
ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic SpasmsSummary on the 8-K
ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO INFANTILE SPASMSEton has licensed Baylor College of Medicine patent rights and submitted an IND to evaluate INCRELEX (mecasermin/IGF-1) as ET-900 in refractory pediatric epileptic spasms — repurposing a commercial asset into a new rare neurological indication and extending the pediatric neurology pivot begun with LIBERVANT.
ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
EIKNEikon TherapeuticsReleaseEikon Therapeutics to Participate in Multiple Investor Conferences in November
DBVTDBV TechnologiesReleaseDBV Technologies to Participate in Upcoming November Investor Conferences
CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
CMPXCompass TherapeuticsReleaseCompass Therapeutics to Participate in Upcoming November Investor Events
CMPSCOMPASS PathwaysReleaseNew Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and CaregiversCMPS has cratered -44.6% from the September highs and -27.3% in today's session alone, with no new clinical data or FDA action in this window — the author needs to address whether the thesis is intact or broken, and why the stock is in freefall.
CMMBChemomab TherapeuticsReleaseChemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is EffectiveThe S-4 is effective and the shareholder vote is set for December 4 — the merger clock is now running, and existing holders face a hard deadline on the CVR record-date decision with the stock down another 45% since my last update.company site may be offline after the acquisition
CLYMClimb BioReleaseClimb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
CLRBCellectar BiosciencesReleaseCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 LEARN MORE
CGTXCognition TherapeuticsReleaseCognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
CBIOCrescent BiopharmaReleaseCrescent Biopharma to Present at November Investor Conferences
BCAXBicara TherapeuticsReleaseBicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
AXSMAxsome TherapeuticsReleaseAxsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update → BD update
AXSMAxsome Therapeutics8-KCurrent report: results of operations, other events · EX-99.1 → BD update
AXSMAxsome Therapeutics10-QQuarterly report → BD update
APVOAptevo Therapeutics8-KCurrent report: other events
ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia VeraThe FDA has cleared AN2's IND for epetraborole in polycythemia vera, completing regulatory authorization across all three planned jurisdictions and setting the clock for a 4Q 2026 first patient — the last scheduled milestone before the 2027 data that carry the entire thesis.
AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
ADCTADC TherapeuticsReleaseADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS RECEIVES U.S. NOTICE OF ALLOWANCE FOR PATENT COVERING ELRAGLUSIB ORAL TABLETS
ABVXAbivaxReleaseAbivax to Participate in Upcoming Fall Investor Conferences

Sunday, November 11

MESOMesoblastReleaseMesoblast Board Changesvia aggregator→ BD updateTwo directors retire ahead of Mesoblast's November 10 AGM — including Philip Krause, whose son's firm was hired to publish the LVAD BLA. The board changes partially address governance concerns I flagged, but the key question — whether George's nominee Voigtman still stands — remains unanswered.